|
1
|
Dinarello CA: Historical insights into
cytokines. Eur J Immunol. 37 (Suppl 1):S34–S45. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Okamura H, Tsutsi H, Komatsu T, Yutsudo M,
Hakura A, Tanimoto T, Torigoe K, Okura T, Nukada Y, Hattori K, et
al: Cloning of a new cytokine that induces IFN-gamma production by
T cells. Nature. 378:88–91. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kaplanski G: Interleukin-18: Biological
properties and role in disease pathogenesis. Immunol Rev.
281:138–153. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Peterson LW and Artis D: Intestinal
epithelial cells: regulators of barrier function and immune
homeostasis. Nat Rev Immunol. 14:141–153. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ng SC, Shi HY, Hamidi N, Underwood FE,
Tang W, Benchimol EI, Panaccione R, Ghosh S, Wu JCY, Chan FKL, et
al: Worldwide incidence and prevalence of inflammatory bowel
disease in the 21st century: A systematic review of
population-based studies. Lancet. 390:2769–2778. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Grivennikov SI: Inflammation and
colorectal cancer: Colitis-associated neoplasia. Semin
Immunopathol. 35:229–244. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nakanishi K, Yoshimoto T, Tsutsui H and
Okamura H: Interleukin-18 regulates both Th1 and Th2 responses,'
(in eng). Annu Rev Immunol. 19:423–474. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bazan JF, Timans JC and Kastelein RA: A
newly defined interleukin-1? Nature. 379:5911996. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ghayur T, Banerjee S, Hugunin M, Butler D,
Herzog L, Carter A, Quintal L, Sekut L, Talanian R, Paskind M, et
al: Caspase-1 processes IFN-gamma-inducing factor and regulates
LPS-induced IFN-gamma production. Nature. 386:619–623. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Novick D: IL-18 and IL-18BP: A unique dyad
in health and disease. Int J Mol Sci. 25:135052024. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dinarello CA, Novick D, Kim S and
Kaplanski G: Interleukin-18 and IL-18 binding protein. Front
Immunol. 4:2892013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Elinav E, Strowig T, Kau AL, Henao-Mejia
J, Thaiss CA, Booth CJ, Peaper DR, Bertin J, Eisenbarth SC, Gordon
JI and Flavell RA: NLRP6 inflammasome regulates colonic microbial
ecology and risk for colitis. Cell. 145:745–757. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nakamura K, Okamura H, Wada M, Nagata K
and Tamura T: Endotoxin-induced serum factor that stimulates gamma
interferon production. Infect Immun. 57:590–595. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nowarski R, Jackson R, Gagliani N, de
Zoete MR, Palm NW, Bailis W, Low JS, Harman CC, Graham M, Elinav E
and Flavell RA: Epithelial IL-18 equilibrium controls barrier
function in colitis. Cell. 163:1444–1456. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bauernfeind F, Rieger A, Schildberg FA,
Knolle PA, Schmid-Burgk JL and Hornung V: NLRP3 inflammasome
activity is negatively controlled by miR-223. J Immunol.
189:4175–4181. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Swanson KV, Deng M and Ting JP: The NLRP3
inflammasome: molecular activation and regulation to therapeutics.
Nat Rev Immunol. 19:477–489. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zheng D, Liwinski T and Elinav E:
Inflammasome activation and regulation: Toward a better
understanding of complex mechanisms. Cell Discov. 6:362020.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhou Y, Gao C, Vong CT, Tao H, Li H, Wang
S and Wang Y: Rhein regulates redox-mediated activation of NLRP3
inflammasomes in intestinal inflammation through
macrophage-activated crosstalk. Br J Pharmacol. 179:1978–1997.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zaki MH, Boyd KL, Vogel P, Kastan MB,
Lamkanfi M and Kanneganti TD: The NLRP3 inflammasome protects
against loss of epithelial integrity and mortality during
experimental colitis. Immunity. 32:379–391. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Levy M, Thaiss CA, Zeevi D, Dohnalová L,
Zilberman-Schapira G, Mahdi JA, David E, Savidor A, Korem T, Herzig
Y, et al: Microbiota-Modulated metabolites shape the intestinal
microenvironment by regulating NLRP6 inflammasome signaling. Cell.
163:1428–1443. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sun Y, Zhang M, Chen CC, Gillilland M III,
Sun X, El-Zaatari M, Huffnagle GB, Young VB, Zhang J, Hong SC, et
al: Stress-induced corticotropin-releasing hormone-mediated NLRP6
inflammasome inhibition and transmissible enteritis in mice.
Gastroenterology. 144:1478–1487. 1487.e1–8. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yasuda K, Nakanishi K and Tsutsui H:
Interleukin-18 in health and disease. Int J Mol Sci. 20:6492019.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hoshino K, Tsutsui H, Kawai T, Takeda K,
Nakanishi K, Takeda Y and Akira S: Cutting edge: Generation of
IL-18 receptor-deficient mice: Evidence for IL-1 receptor-related
protein as an essential IL-18 binding receptor. J Immunol.
162:5041–5044. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kim SH, Reznikov LL, Stuyt RJ, Selzman CH,
Fantuzzi G, Hoshino T, Young HA and Dinarello CA: Functional
reconstitution and regulation of IL-18 activity by the IL-18R beta
chain. J Immunol. 166:148–154. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wu C, Sakorafas P, Miller R, McCarthy D,
Scesney S, Dixon R and Ghayur T: IL-18 receptor beta-induced
changes in the presentation of IL-18 binding sites affect ligand
binding and signal transduction. J Immunol. 170:5571–5577. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tsutsumi N, Kimura T, Arita K, Ariyoshi M,
Ohnishi H, Yamamoto T, Zuo X, Maenaka K, Park EY, Kondo N, et al:
The structural basis for receptor recognition of human
interleukin-18. Nat Commun. 5:53402014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Matsumoto S, Tsuji-Takayama K, Aizawa Y,
Koide K, Takeuchi M, Ohta T and Kurimoto M: Interleukin-18
activates NF-kappaB in murine T helper type 1 cells. Biochem
Biophys Res Commun. 234:454–457. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Okamura H, Nagata K, Komatsu T, Tanimoto
T, Nukata Y, Tanabe F, Akita K, Torigoe K, Okura T, Fukuda S, et
al: A novel costimulatory factor for gamma interferon induction
found in the livers of mice causes endotoxic shock. Infect Immun.
63:3966–3972. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zheng Y, Valdez PA, Danilenko DM, Hu Y, Sa
SM, Gong Q, Abbas AR, Modrusan Z, Ghilardi N, de Sauvage FJ and
Ouyang W: Interleukin-22 mediates early host defense against
attaching and effacing bacterial pathogens. Nat Med. 14:282–289.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li J, Wu Z, Pan Y, Chen Y, Chu J, Cong Y
and Fang Q: GNL3L exhibits pro-tumor activities via NF-κB pathway
as a poor prognostic factor in acute myeloid leukemia. J Cancer.
15:4072–4080. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Shen J, Zhang Y, Tang W, Yang M, Cheng T,
Chen Y, Yu S, Guo Q, Cao L, Wang X, et al: Short IL-18 generated by
caspase-3 cleavage mobilizes NK cells to suppress tumor growth. Nat
Immunol. 26:416–428. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Novick D, Kim SH, Fantuzzi G, Reznikov LL,
Dinarello CA and Rubinstein M: Interleukin-18 binding protein: a
novel modulator of the Th1 cytokine response. Immunity. 10:127–136.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Aizawa Y, Akita K, Taniai M, Torigoe K,
Mori T, Nishida Y, Ushio S, Nukada Y, Tanimoto T, Ikegami H, et al:
Cloning and expression of interleukin-18 binding protein. FEBS
Lett. 445:338–342. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Novick D and Rubinstein M: The tale of
soluble receptors and binding proteins: From bench to bedside.
Cytokine Growth Factor Rev. 18:525–1533. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ludwiczek O, Kaser A, Novick D, Dinarello
CA, Rubinstein M and Tilg H: Elevated systemic levels of free
interleukin-18 (IL-18) in patients with Crohn's disease. Eur
Cytokine Netw. 16:27–33. 2005.PubMed/NCBI
|
|
36
|
Naftali T, Novick D, Gabay G, Rubinstein M
and Novis B: Interleukin-18 and its binding protein in patients
with inflammatory bowel disease during remission and exacerbation.
Isr Med Assoc J. 9:504–508. 2007.PubMed/NCBI
|
|
37
|
Kinoshita M, Miyazaki H, Ono S and Seki S:
Immunoenhancing therapy with interleukin-18 against bacterial
infection in immunocompromised hosts after severe surgical stress.
J Leukoc Biol. 93:689–698. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kinoshita K, Yamagata T, Nozaki Y,
Sugiyama M, Ikoma S, Funauchi M and Kanamaru A: Blockade of IL-18
receptor signaling delays the onset of autoimmune disease in
MRL-Faslpr mice. J Immunol. 173:5312–5318. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kinoshita M, Miyazaki H, Ono S, Inatsu A,
Nakashima H, Tsujimoto H, Shinomiya N, Saitoh D and Seki S:
Enhancement of neutrophil function by interleukin-18 therapy
protects burn-injured mice from methicillin-resistant
Staphylococcus aureus. Infect Immun. 79:2670–2780. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kinoshita M, Seki S, Ono S, Shinomiya N
and Hiraide H: Paradoxical effect of IL-18 therapy on the severe
and mild Escherichia coli infections in burn-injured mice. Ann
Surg. 240:313–320. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kinoshita M, Kuranaga N, Matsumoto A, Ono
S, Shinomiya N, Hiraide H and Seki S: Multiple interleukin-18
injections promote both mouse Th1 and Th2 responses after sublethal
Escherichia coli infection. Clin Exp Immunol. 143:41–49. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kinoshita M, Shinomiya N, Ono S, Tsujimoto
H, Kawabata T, Matsumoto A, Hiraide H and Seki S: Restoration of
natural IgM production from liver B cells by exogenous IL-18
improves the survival of burn-injured mice infected with
Pseudomonas aeruginosa. J Immunol. 177:4627–4635. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Grencis RK: Th2-mediated host protective
immunity to intestinal nematode infections. Philos Trans R Soc Lond
B Biol Sci. 352:1377–1384. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Sasaki Y, Yoshimoto T, Maruyama H, Tegoshi
T, Ohta N, Arizono N and Nakanishi K: IL-18 with IL-2 protects
against Strongyloides venezuelensis infection by activating mucosal
mast cell-dependent type 2 innate immunity. J Exp Med. 202:607–616.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Helmby H and Grencis RK: IL-18 regulates
intestinal mastocytosis and Th2 cytokine production independently
of IFN-gamma during Trichinella spiralis infection. J Immunol.
169:2553–2560. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Helmby H, Takeda K, Akira S and Grencis
RK: Interleukin (IL)-18 promotes the development of chronic
gastrointestinal helminth infection by downregulating IL-13. J Exp
Med. 194:355–364. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Hepworth MR, Hardman MJ and Grencis RK:
The role of sex hormones in the development of Th2 immunity in a
gender-biased model of Trichuris muris infection. Eur J Immunol.
40:406–416. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Takeda K, Tsutsui H, Yoshimoto T, Adachi
O, Yoshida N, Kishimoto T, Okamura H, Nakanishi K and Akira S:
Defective NK cell activity and Th1 response in IL-18-deficient
mice. Immunity. 8:383–390. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Kobayashi K, Nakata N, Kai M, Kasama T,
Hanyuda Y and Hatano Y: Decreased expression of cytokines that
induce type 1 helper T cell/interferon-gamma responses in
genetically susceptible mice infected with Mycobacterium avium.
Clin Immunol Immunopathol. 85:112–116. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Sugawara I, Yamada H, Kaneko H, Mizuno S,
Takeda K and Akira S: Role of interleukin-18 (IL-18) in
mycobacterial infection in IL-18-gene-disrupted mice. Infect Immun.
67:2585–2589. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Schneider BE, Korbel D, Hagens K, Koch M,
Raupach B, Enders J, Kaufmann SH, Mittrücker HW and Schaible UE: A
role for IL-18 in protective immunity against Mycobacterium
tuberculosis. Eur J Immunol. 40:396–405. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Zhang B, Xiao L, Qiu Q, Miao L, Yan S and
Zhou S: Association between IL-18, IFN-γ and TB susceptibility: A
systematic review and meta-analysis. Ann Palliat Med.
10:10878–10886. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Mastroeni P, Clare S, Khan S, Harrison JA,
Hormaeche CE, Okamura H, Kurimoto M and Dougan G: Interleukin 18
contributes to host resistance and gamma interferon production in
mice infected with virulent Salmonella typhimurium. Infect Immun.
67:478–483. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Bohn E, Sing A, Zumbihl R, Bielfeldt C,
Okamura H, Kurimoto M, Heesemann J and Autenrieth IB: IL-18
(IFN-gamma-inducing factor) regulates early cytokine production in,
and promotes resolution of, bacterial infection in mice. J Immunol.
160:299–307. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Sansonetti PJ, Phalipon A, Arondel J,
Thirumalai K, Banerjee S, Akira S, Takeda K and Zychlinsky A:
Caspase-1 activation of IL-1beta and IL-18 are essential for
Shigella flexneri-induced inflammation. Immunity. 12:581–590. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Qureshi MH, Zhang T, Koguchi Y, Nakashima
K, Okamura H, Kurimoto M and Kawakami K: Combined effects of IL-12
and IL-18 on the clinical course and local cytokine production in
murine pulmonary infection with Cryptococcus neoformans. Eur J
Immunol. 29:643–649. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Kawakami K, Qureshi MH, Koguchi Y, Zhang
T, Okamura H, Kurimoto M and Saito A: Role of TNF-alpha in the
induction of fungicidal activity of mouse peritoneal exudate cells
against Cryptococcus neoformans by IL-12 and IL-18. Cell Immunol.
193:9–16. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Brummer E: Human defenses against
Cryptococcus neoformans: An update. Mycopathologia. 143:121–125.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Kawakami K, Koguchi Y, Qureshi MH,
Miyazato A, Yara S, Kinjo Y, Iwakura Y, Takeda K, Akira S, Kurimoto
M and Saito A: IL-18 contributes to host resistance against
infection with Cryptococcus neoformans in mice with defective IL-12
synthesis through induction of IFN-gamma production by NK cells. J
Immunol. 165:941–947. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Wei XO, Leung BP, Niedbala W, Piedrafita
D, Feng GJ, Sweet M, Dobbie L, Smith AJ and Liew FY: Altered immune
responses and susceptibility to Leishmania major and Staphylococcus
aureus infection in IL-18-deficient mice. J Immunol. 163:2821–2828.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Ohkusu K, Yoshimoto T, Takeda K, Ogura T,
Kashiwamura S, Iwakura Y, Akira S, Okamura H and Nakanishi K:
Potentiality of interleukin-18 as a useful reagent for treatment
and prevention of Leishmania major infection. Infect Immun.
68:2449–2456. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Monteforte GM, Takeda K, Rodriguez-Sosa M,
Akira S, David JR and Satoskar AR: Genetically resistant mice
lacking IL-18 gene develop Th1 response and control cutaneous
Leishmania major infection. J Immunol. 164:5890–5893. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Muñoz M, Eidenschenk C, Ota N, Wong K,
Lohmann U, Kühl AA, Wang X, Manzanillo P, Li Y, Rutz S, et al:
Interleukin-22 induces interleukin-18 expression from epithelial
cells during intestinal infection. Immunity. 42:321–331. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Valle-Noguera A, Sancho-Temiño L,
Castillo-González R, Villa-Gómez C, Gomez-Sánchez MJ, Ochoa-Ramos
A, Yagüe-Fernández P, Soler Palacios B, Zorita V, Raposo-Ponce B,
et al: IL-18-induced HIF-1α in ILC3s ameliorates the inflammation
of C. rodentium-induced colitis. Cell Rep. 42:1135082023.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Berkachy R, Mishra V, Biswas P and Frankel
G: Citrobacter rodentium infection activates colonic lamina propria
group 2 innate lymphoid cells. PLoS Pathog. 21:e10132762025.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Backert I, Koralov SB, Wirtz S, Kitowski
V, Billmeier U, Martini E, Hofmann K, Hildner K, Wittkopf N, Brecht
K, et al: STAT3 activation in Th17 and Th22 cells controls
IL-22-mediated epithelial host defense during infectious colitis. J
Immunol. 193:3779–3791. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Yang W, Yu T, Huang X, Bilotta AJ, Xu L,
Lu Y, Sun J, Pan F, Zhou J, Zhang W, et al: Intestinal
microbiota-derived short-chain fatty acids regulation of immune
cell IL-22 production and gut immunity. Nat Commun. 11:44572020.
View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Chiang HY, Lu HH, Sudhakar JN, Chen YW,
Shih NS, Weng YT and Shui JW: IL-22 initiates an IL-18-dependent
epithelial response circuit to enforce intestinal host defence. Nat
Commun. 13:8742022. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Han X, Allaire JM, Crowley SM, Chan JJ,
Lau K, Zhang C, Hirota SA, Bergstrom K, Knodler LA and Vallance BA:
Inflammasome activation links enteric Salmonella Typhimurium
infection to a rapid, cytokine-dependent increase in intestinal
mucin release. Gut Microbes. 16:24133722024. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Zhang B, Chassaing B, Shi Z, Uchiyama R,
Zhang Z, Denning TL, Crawford SE, Pruijssers AJ, Iskarpatyoti JA,
Estes MK, et al: Viral infection. Prevention and cure of rotavirus
infection via TLR5/NLRC4-mediated production of IL-22 and IL-18.
Science. 346:861–865. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Gao YG, Jin Y, Liu YL and Ye YX:
(Variation and significance of serum and stool IL-18 and IFN-gamma
levels in children with rotavirus enteritis). Zhongguo Dang Dai Er
Ke Za Zhi. 8:304–306. 2006.(In Chinese). PubMed/NCBI
|
|
72
|
Ewald SE, Chavarria-Smith J and Boothroyd
JC: NLRP1 is an inflammasome sensor for Toxoplasma gondii. Infect
Immun. 82:460–468. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Vossenkämper A, Struck D,
Alvarado-Esquivel C, Went T, Takeda K, Akira S, Pfeffer K, Alber G,
Lochner M, Förster I and Liesenfeld O: Both IL-12 and IL-18
contribute to small intestinal Th1-type immunopathology following
oral infection with Toxoplasma gondii, but IL-12 is dominant over
IL-18 in parasite control. Eur J Immunol. 34:3197–3207. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Liesenfeld O, Kosek J, Remington JS and
Suzuki Y: Association of CD4+ T cell-dependent,
interferon-gamma-mediated necrosis of the small intestine with
genetic susceptibility of mice to peroral infection with Toxoplasma
gondii. J Exp Med. 184:597–607. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Liesenfeld O, Kang H, Park D, Nguyen TA,
Parkhe CV, Watanabe H, Abo T, Sher A, Remington JS and Suzuki Y:
TNF-alpha, nitric oxide and IFN-gamma are all critical for
development of necrosis in the small intestine and early mortality
in genetically susceptible mice infected perorally with Toxoplasma
gondii. Parasite Immunol. 21:365–376. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Bała G, Swincow G, Odrowaz-Sypniewska G
and Czerwionka-Szaflarska M: Interleukin 13 and 18 serum
concentration in children with cow milk hypersensitivity. Med Wieku
Rozwoj. 8:33–42. 2004.(In Polish). PubMed/NCBI
|
|
77
|
Verma AK, Verma AK, Kandikattu HK, Manohar
M, Shukla A, Upparahalli Venkateshaiah S, Zhu X and Mishra A:
Intestinal overexpression of IL-18 promotes eosinophils-mediated
allergic disorders. Immunology. 157:110–121. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Yoshimoto T, Min B, Sugimoto T, Hayashi N,
Ishikawa Y, Sasaki Y, Hata H, Takeda K, Okumura K, Van Kaer L, et
al: Nonredundant roles for CD1d-restricted natural killer T cells
and conventional CD4+ T cells in the induction of immunoglobulin E
antibodies in response to interleukin 18 treatment of mice. J Exp
Med. 197:997–1005. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Enoksson SL, Grasset EK, Hägglöf T,
Mattsson N, Kaiser Y, Gabrielsson S, McGaha TL, Scheynius A and
Karlsson MC: The inflammatory cytokine IL-18 induces self-reactive
innate antibody responses regulated by natural killer T cells. Proc
Natl Acad Sci USA. 108:E1399–E1407. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Yoshimoto T, Mizutani H, Tsutsui H,
Noben-Trauth N, Yamanaka K, Tanaka M, Izumi S, Okamura H, Paul WE
and Nakanishi K: IL-18 induction of IgE: dependence on CD4+ T
cells, IL-4 and STAT6. Nat Immunol. 1:132–137. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Loher F, Bauer C, Landauer N, Schmall K,
Siegmund B, Lehr HA, Dauer M, Schoenharting M, Endres S and Eigler
A: The interleukin-1 beta-converting enzyme inhibitor pralnacasan
reduces dextran sulfate sodium-induced murine colitis and T helper
1 T-cell activation. J Pharmacol Exp Ther. 308:583–590. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Siegmund B, Fantuzzi G, Rieder F,
Gamboni-Robertson F, Lehr HA, Hartmann G, Dinarello CA, Endres S
and Eigler A: Neutralization of interleukin-18 reduces severity in
murine colitis and intestinal IFN-gamma and TNF-alpha production.
Am J Physiol Regul Integr Comp Physiol. 281:R1264–R1273. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Pallone F and Monteleone G: Interleukin 12
and Th1 responses in inflammatory bowel disease. Gut. 43:735–736.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Monteleone G, MacDonald TT, Wathen NC,
Pallone F and Pender SL: Enhancing Lamina propria Th1 cell
responses with interleukin 12 produces severe tissue injury.
Gastroenterology. 117:1069–1077. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Pages F, Berger A, Lebel-Binay S,
Zinzindohoue F, Danel C, Piqueras B, Carriere O, Thiounn N, Cugnenc
PH and Fridman WH: Proinflammatory and antitumor properties of
interleukin-18 in the gastrointestinal tract. Immunol Lett.
75:9–14. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Dinarello CA, Novick D, Puren AJ, Fantuzzi
G, Shapiro L, Mühl H, Yoon DY, Reznikov LL, Kim SH and Rubinstein
M: Overview of interleukin-18: More than an interferon-gamma
inducing factor. J Leukoc Biol. 63:658–664. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Jarry A, Bossard C, Droy-Dupré L, Volteau
C, Bourreille A, Meurette G, Mosnier JF and Laboisse CL:
Heterogeneity of subordination of the IL-18/IFN-γ axis to caspase-1
among patients with Crohn's disease. Lab Invest. 95:1207–1217.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Pizarro TT, Michie MH, Bentz M,
Woraratanadharm J, Smith MF Jr, Foley E, Moskaluk CA, Bickston SJ
and Cominelli F: IL-18, a novel immunoregulatory cytokine, is
up-regulated in Crohn's disease: expression and localization in
intestinal mucosal cells. J Immunol. 162:6829–6835. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Monteleone G, Trapasso F, Parrello T,
Biancone L, Stella A, Iuliano R, Luzza F, Fusco A and Pallone F:
Bioactive IL-18 expression is up-regulated in Crohn's disease. J
Immunol. 163:143–147. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Okazawa A, Kanai T, Watanabe M, Yamazaki
M, Inoue N, Ikeda M, Kurimoto M, Ishii H and Hibi T: Th1-mediated
intestinal inflammation in Crohn's disease may be induced by
activation of lamina propria lymphocytes through synergistic
stimulation of interleukin-12 and interleukin-18 without T cell
receptor engagement. Am J Gastroenterol. 97:3108–3117. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Strober W, Fuss IJ, Ehrhardt RO, Neurath
M, Boirivant M and Lúdvíksson BR: Mucosal immunoregulation and
inflammatory bowel disease: New insights from murine models of
inflammation. Scand J Immunol. 48:453–458. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Kanai T, Watanabe M, Okazawa A, Sato T,
Yamazaki M, Okamoto S, Ishii H, Totsuka T, Iiyama R, Okamoto R, et
al: Macrophage-derived IL-18-mediated intestinal inflammation in
the murine model of Crohn's disease. Gastroenterology. 121:875–888.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Hölttä V, Klemetti P, Sipponen T,
Westerholm-Ormio M, Kociubinski G, Salo H, Räsänen L, Kolho KL,
Färkkilä M, Savilahti E and Vaarala O: IL-23/IL-17 immunity as a
hallmark of Crohn's disease. Inflamm Bowel Dis. 14:1175–1184. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Wang Z, Li C, He X, Xu K, Xue Z, Wang T,
Xu Z and Liu X: Platycodon grandiflorum root fermentation broth
reduces inflammation in a mouse IBD model through the
AMPK/NF-κB/NLRP3 pathway. Food Funct. 13:3946–3956. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Verma A, Pittala S, Alhozeel B,
Shteinfer-Kuzmine A, Ohana E, Gupta R, Chung JH and Shoshan-Barmatz
V: The role of the mitochondrial protein VDAC1 in inflammatory
bowel disease: A potential therapeutic target. Mol Ther.
30:726–744. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
West AP and Shadel GS: Mitochondrial DNA
in innate immune responses and inflammatory pathology. Nat Rev
Immunol. 17:363–375. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Shoshan-Barmatz V, De Pinto V,
Zweckstetter M, Raviv Z, Keinan N and Arbel N: VDAC, a
multi-functional mitochondrial protein regulating cell life and
death. Mol Aspects Med. 31:227–285. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Geula S, Ben-Hail D and Shoshan-Barmatz V:
Structure-based analysis of VDAC1: N-terminus location,
translocation, channel gating and association with anti-apoptotic
proteins. Biochem J. 444:475–485. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Keinan N, Tyomkin D and Shoshan-Barmatz V:
Oligomerization of the mitochondrial protein voltage-dependent
anion channel is coupled to the induction of apoptosis. Mol Cell
Biol. 30:5698–5709. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Marchi S, Patergnani S and Pinton P: The
endoplasmic reticulum-mitochondria connection: one touch, multiple
functions. Biochim Biophys Acta. 1837:461–469. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Shoshan-Barmatz V, Maldonado EN and Krelin
Y: VDAC1 at the crossroads of cell metabolism, apoptosis and cell
stress. Cell Stress. 1:11–36. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Lin C, Jiang Z, Cao L, Zou H and Zhu X:
Role of NLRP3 inflammasome in systemic sclerosis. Arthritis Res
Ther. 24:1962022. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Yu J, Nagasu H, Murakami T, Hoang H,
Broderick L, Hoffman HM and Horng T: Inflammasome activation leads
to Caspase-1-dependent mitochondrial damage and block of mitophagy.
Proc Natl Acad Sci USA. 111:15514–15519. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Ikegami S, Maeda K, Urano T, Mu J,
Nakamura M, Yamamura T, Sawada T, Ishikawa E, Yamamoto K, Muto H,
et al: Monoclonal antibody against mature interleukin-18
ameliorates colitis in mice and improves epithelial barrier
function. Inflamm Bowel Dis. 30:1353–1366. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Li P, Chen G, Zhang J, Pei C, Chen Y, Gong
J, Deng S, Cai K, Li H, Wang D, et al: Live Lactobacillus
acidophilus alleviates ulcerative colitis via the
SCFAs/mitophagy/NLRP3 inflammasome axis. Food Funct. 13:2985–2997.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Lazaridis LD, Pistiki A,
Giamarellos-Bourboulis EJ, Georgitsi M, Damoraki G, Polymeros D,
Dimitriadis GD and Triantafyllou K: Activation of NLRP3
inflammasome in inflammatory bowel disease: Differences between
Crohn's disease and ulcerative colitis. Dig Dis Sci. 62:2348–2356.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Kanneganti TD: Inflammatory bowel disease
and the NLRP3 inflammasome. N Engl J Med. 377:694–696. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Wang W, Li G, De Wu, Luo Z, Pan P, Tian M,
Wang Y, Xiao F, Li A, Wu K, et al: Zika virus infection induces
host inflammatory responses by facilitating NLRP3 inflammasome
assembly and interleukin-1β secretion. Nat Commun. 9:1062018.
View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Ratsimandresy RA, Indramohan M,
Dorfleutner A and Stehlik C: The AIM2 inflammasome is a central
regulator of intestinal homeostasis through the IL-18/IL-22/STAT3
pathway. Cell Mol Immunol. 14:127–142. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Rathinam VA, Jiang Z, Waggoner SN, Sharma
S, Cole LE, Waggoner L, Vanaja SK, Monks BG, Ganesan S, Latz E, et
al: The AIM2 inflammasome is essential for host defense against
cytosolic bacteria and DNA viruses. Nat Immunol. 11:395–402. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Huber S, Gagliani N, Zenewicz LA, Huber
FJ, Bosurgi L, Hu B, Hedl M, Zhang W, O'Connor W Jr, Murphy AJ, et
al: IL-22BP is regulated by the inflammasome and modulates
tumorigenesis in the intestine. Nature. 491:259–263. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Pickert G, Neufert C, Leppkes M, Zheng Y,
Wittkopf N, Warntjen M, Lehr HA, Hirth S, Weigmann B, Wirtz S, et
al: STAT3 links IL-22 signaling in intestinal epithelial cells to
mucosal wound healing. J Exp Med. 206:1465–1472. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Grivennikov S, Karin E, Terzic J, Mucida
D, Yu GY, Vallabhapurapu S, Scheller J, Rose-John S, Cheroutre H,
Eckmann L and Karin M: IL-6 and Stat3 are required for survival of
intestinal epithelial cells and development of colitis-associated
cancer. Cancer Cell. 15:103–113. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Kong C, Yan X, Liu Y, Huang L, Zhu Y, He
J, Gao R, Kalady MF, Goel A, Qin H and Ma Y: Ketogenic diet
alleviates colitis by reduction of colonic group 3 innate lymphoid
cells through altering gut microbiome. Signal Transduct Target
Ther. 6:1542021. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Wilson JE, Petrucelli AS, Chen L,
Koblansky AA, Truax AD, Oyama Y, Rogers AB, Brickey WJ, Wang Y,
Schneider M, et al: Inflammasome-independent role of AIM2 in
suppressing colon tumorigenesis via DNA-PK and Akt. Nat Med.
21:906–913. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Pu Z, Che Y, Zhang W, Sun H, Meng T, Xie
H, Cao L and Hao H: Dual roles of IL-18 in colitis through
regulation of the function and quantity of goblet cells. Int J Mol
Med. 43:2291–2302. 2019.PubMed/NCBI
|
|
117
|
Mielke LA, Jones SA, Raverdeau M, Higgs R,
Stefanska A, Groom JR, Misiak A, Dungan LS, Sutton CE, Streubel G,
et al: Retinoic acid expression associates with enhanced IL-22
production by γδ T cells and innate lymphoid cells and attenuation
of intestinal inflammation. J Exp Med. 210:1117–1124. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Kalina U, Koyama N, Hosoda T, Nuernberger
H, Sato K, Hoelzer D, Herweck F, Manigold T, Singer MV, Rossol S
and Böcker U: Enhanced production of IL-18 in butyrate-treated
intestinal epithelium by stimulation of the proximal promoter
region. Eur J Immunol. 32:2635–2643. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Nakamori M, Iwahashi M, Nakamura M, Ueda
K, Zhang X and Yamaue H: Intensification of antitumor effect by T
helper 1-dominant adoptive immunogene therapy for advanced
orthotopic colon cancer. Clin Cancer Res. 9:2357–2365.
2003.PubMed/NCBI
|
|
120
|
Hashimoto W, Osaki T, Okamura H, Robbins
PD, Kurimoto M, Nagata S, Lotze MT and Tahara H: Differential
antitumor effects of administration of recombinant IL-18 or
recombinant IL-12 are mediated primarily by Fas-Fas ligand- and
perforin-induced tumor apoptosis, respectively. J Immunol.
163:583–589. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Osaki T, Péron JM, Cai Q, Okamura H,
Robbins PD, Kurimoto M, Lotze MT and Tahara H: IFN-gamma-inducing
factor/IL-18 administration mediates IFN-gamma- and
IL-12-independent antitumor effects. J Immunol. 160:1742–1749.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Tian H, Shi G, Yang G, Zhang J, Li Y, Du
T, Wang J, Xu F, Cheng L, Zhang X, et al: Retraction Note: Cellular
immunotherapy using irradiated lung cancer cell vaccine
co-expressing GM-CSF and IL-18 can induce significant antitumor
effects. BMC Cancer. 23:6122023. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Zhang B, Wu KF, Lin YM, Ma XT, Rao Q,
Zheng GG, Cao ZY, Li G and Song YH: Gene transfer of pro-IL-18 and
IL-1beta converting enzyme cDNA induces potent antitumor effects in
L1210 cells. Leukemia. 18:817–825. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Zaki MH, Lamkanfi M and Kanneganti TD: The
Nlrp3 inflammasome: Contributions to intestinal homeostasis. Trends
Immunol. 32:171–179. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Tanaka F, Hashimoto W, Okamura H, Robbins
PD, Lotze MT and Tahara H: Rapid generation of potent and
tumor-specific cytotoxic T lymphocytes by interleukin 18 using
dendritic cells and natural killer cells. Cancer Res. 60:4838–4844.
2000.PubMed/NCBI
|
|
126
|
Salcedo R, Worschech A, Cardone M, Jones
Y, Gyulai Z, Dai RM, Wang E, Ma W, Haines D, O'hUigin C, et al:
MyD88-mediated signaling prevents development of adenocarcinomas of
the colon: Role of interleukin 18. J Exp Med. 207:1625–1636. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Zaki MH, Vogel P, Body-Malapel M, Lamkanfi
M and Kanneganti TD: IL-18 production downstream of the Nlrp3
inflammasome confers protection against colorectal tumor formation.
J Immunol. 185:4912–4920. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Gatault G, Delbeke M, Driss V, Sarazin A,
Dendooven A, Kahn JE, Lefèvre G and Capron M: IL-18 is involved in
eosinophil-mediated tumoricidal activity against a colon carcinoma
cell line by upregulating LFA-1 and ICAM-1. J Immunol.
195:2483–2492. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Legrand F, Driss V, Delbeke M, Loiseau S,
Hermann E, Dombrowicz D and Capron M: Human eosinophils exert TNF-α
and granzyme A-mediated tumoricidal activity toward colon carcinoma
cells. J Immunol. 185:7443–7451. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Pages F, Vives V, Sautès-Fridman C,
Fossiez F, Berger A, Cugnenc PH, Tartour E and Fridman WH: Control
of tumor development by intratumoral cytokines. Immunol Lett.
68:135–139. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Tartour E, Gey A, Sastre-Garau X, Lombard
Surin I, Mosseri V and Fridman WH: Prognostic value of intratumoral
interferon gamma messenger RNA expression in invasive cervical
carcinomas. J Natl Cancer Inst. 90:287–294. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Tartour E and Fridman WH: Cytokines and
cancer. Int Rev Immunol. 16:683–704. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Yamanaka K, Hara I, Nagai H, Miyake H,
Gohji K, Micallef MJ, Kurimoto M, Arakawa S and Kamidono S:
Synergistic antitumor effects of interleukin-12 gene transfer and
systemic administration of interleukin-18 in a mouse bladder cancer
model. Cancer Immunol Immunother. 48:297–302. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Micallef MJ, Yoshida K, Kawai S, Hanaya T,
Kohno K, Arai S, Tanimoto T, Torigoe K, Fujii M, Ikeda M and
Kurimoto M: In vivo antitumor effects of murine
interferon-gamma-inducing factor/interleukin-18 in mice bearing
syngeneic Meth A sarcoma malignant ascites. Cancer Immunol
Immunother. 43:361–367. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Cao R, Farnebo J, Kurimoto M and Cao Y:
Interleukin-18 acts as an angiogenesis and tumor suppressor. FASEB
J. 13:2195–2202. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Heuer JG, Tucker-McClung C and Hock RA:
Neuroblastoma cells expressing mature IL-18, but not proIL-18,
induce a strong and immediate antitumor immune response. J
Immunother. 22:324–335. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Coughlin CM, Salhany KE, Wysocka M, Aruga
E, Kurzawa H, Chang AE, Hunter CA, Fox JC, Trinchieri G and Lee WM:
Interleukin-12 and interleukin-18 synergistically induce murine
tumor regression which involves inhibition of angiogenesis. J Clin
Invest. 101:1441–1452. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Osaki T, Hashimoto W, Gambotto A, Okamura
H, Robbins PD, Kurimoto M, Lotze MT and Tahara H: Potent antitumor
effects mediated by local expression of the mature form of the
interferon-gamma inducing factor, interleukin-18 (IL-18). Gene
Ther. 6:808–815. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Li B, Wang F, Ma C, Hao T, Geng L and
Jiang H: Predictive value of IL-18 and IL-10 in the prognosis of
patients with colorectal cancer. Oncol Lett. 18:713–719.
2019.PubMed/NCBI
|
|
140
|
Kim KE, Song H, Kim TS, Yoon D, Kim CW,
Bang SI, Hur DY, Park H and Cho DH: Interleukin-18 is a critical
factor for vascular endothelial growth factor-enhanced migration in
human gastric cancer cell lines. Oncogene. 26:1468–1476. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Kim J, Kim C, Kim TS, Bang SI, Yang Y,
Park H and Cho D: IL-18 enhances thrombospondin-1 production in
human gastric cancer via JNK pathway. Biochem Biophys Res Commun.
344:1284–1289. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Kanai T, Watanabe M, Okazawa A, Nakamaru
K, Okamoto M, Naganuma M, Ishii H, Ikeda M, Kurimoto M and Hibi T:
Interleukin 18 is a potent proliferative factor for intestinal
mucosal lymphocytes in Crohn's disease. Gastroenterology.
119:1514–1523. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Li LJ, Gong C, Zhao MH and Feng BS: Role
of interleukin-22 in inflammatory bowel disease. World J
Gastroenterol. 20:18177–18188. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Zhang H, Shi Y, Ying J, Chen Y, Guo R,
Zhao X, Jia L, Xiong J and Jiang F: A bibliometric and visualized
research on global trends of immune checkpoint inhibitors related
complications in melanoma, 2011–2021. Front Endocrinol (Lausanne).
14:11646922023. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Zhang B, Lau LY, Chen Y and Xie R:
Bibliometric analysis of immune-related acute kidney injury induced
by cancer immunotherapy (2000–2025). Naunyn Schmiedebergs Arch
Pharmacol. 399:2647–2662. 2026. View Article : Google Scholar : PubMed/NCBI
|
